Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Inclusion Criteria: * Men and women ≥ 18 years old * Primary tumor amenable to safe research biopsy. A tumor biopsy is required for study entry. * Histology proven epithelial or biphasic MPM * Diagnostic core biopsy specimens must be reviewed by faculty pathologist at SKCC, MDACC, or UMGCCC. * Either a formalin fixed paraffin block that has been confirmed by a pathologist to contain tumor or a minimum of twenty 5-micron tissue sections (slides) of tumor biopsy sample must be available for biomarker evaluation (study pathologist must review for adequacy of sampling). This can be obtained from archived tissues if adequate, or from a new biopsy as needed. * Stage I-III and deemed to be potentially surgically resectable as assessed by faculty surgeon at SKCC, MDACC, or UMGCCC * ECOG performance status 0-1 * Adequate organ function as follows: * Leukocytes ≥ 2,000/mm3 * Absolute neutrophil count (ANC) ≥ 1000/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin ≥ 9 g/Dl * Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥40 mL/min (if using the Cockcroft-Gault formula below): Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL * Total Bilirubin ≤ 1.5 x institutional ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL) * AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 3 times the institutional upper limit of …